Reckitt Benckiser Group (3RB1) Q2 2026 Earnings Report
DE:3RB1 Q2 2026 EPS Results
- Actual EPS
- EUR 0.24
- Consensus EPS
- EUR 0.34
- Beat/Miss
- Missed by -EUR 0.10
- One Year Ago EPS
- EUR 0.35
DE:3RB1 Q2 2026 Revenue Results
- Actual Revenue
- EUR 7.70B
- Expected Revenue
- EUR 3.60B
- Beat/Miss
- Beat by +EUR 4.10B
- YoY Revenue Growth
- -4.73%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 07/29/2026
- Time
- Before Open
- Conference Call
- Wednesday, July 29, 2026
Reckitt Benckiser Group's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call conveyed a constructive tone driven by clear Q2 acceleration, strong emerging market execution and successful innovation launches, supported by disciplined cost actions under the Fuel for Growth program and active shareholder returns. Material lowlights remain: the dilutive impact of the Essential Home divestment (pressuring EPS and operating profit), gross margin headwinds from higher input costs and commodity volatility, weakness in Household Care/Auto Dish and some developed-market softness. Management reiterated guidance and emphasized confidence in mitigation plans, leaving the narrative net positive but balanced by identifiable execution and macro risks.
Management reiterated full‑year guidance for Core Reckitt of 4–5% like‑for‑like net revenue growth and adjusted operating profit margin of 24.9–25.6% (Core Reckitt & Mead Johnson), expecting a significantly stronger second half; H1 saw group like‑for‑like net revenue +2.6% (Core Reckitt +2.7%) with Q2 acceleration to +4.7% group / +4.2% Core Reckitt, H1 adjusted EPS 152.1p (‑9.7% y/y), H1 free cash flow £419m and net debt/EBITDA 2.5x. The company expects emerging markets to deliver H2 growth similar to H1, Europe to return to like‑for‑like growth in H2, North America to be stronger and weighted to Q4, and seasonal OTC incidence to be slightly higher than the prior season; it reiterated Fuel for Growth targets (fixed costs below 19% of net revenue by end‑2027), with program cost ~£1bn (≈£350m in 2026), announced a new £500m 12‑month buyback, increased the interim dividend by 5%, and noted continued actions to mitigate volatile commodity costs.
- Q2 Acceleration and Revenue GrowthCore Reckitt like-for-like net revenue grew 2.7% in H1 with a stronger Q2 performance of 4.2%; Group (Core Reckitt + Mead Johnson) like-for-like net revenue grew 2.6% in H1 with Q2 at 4.7%.
- Emerging Markets OutperformanceEmerging markets delivered strong growth: like-for-like net revenue up 8.5% in H1 and 9.4% in Q2; excluding Russia Hygiene emerging markets grew 10.3% in the half. China achieved its 12th consecutive quarter of double-digit growth.
- Innovation Driving Premiumization and Share GainsMultiple successful launches: Dettol Activ Botany significantly exceeding expectations in China and expanding to ASEAN/Europe; Vanish Turbo returned Vanish to like-for-like growth in Q2; Durex Intensity expanded to 19 markets; initial shipments of Mucinex 12 Hour Cold & Fever began in June supporting North America activity.
- Margin Resilience and Fuel for Growth ProgressCore Reckitt & Mead Johnson adjusted operating profit margin was 23.6% in H1 (100 bps lower YoY but ahead of expectations). Fixed costs broadly flat at 20.1% of net revenue as Fuel for Growth savings offset stranded costs; program on track to drive fixed costs below 19% of net revenue by end-2027; program cost ~GBP 1bn, ~GBP 350m in 2026.
- Strong Shareholder Returns and Capital AllocationReturned ~GBP 3bn to shareholders in the period (special & full year dividends and buybacks); announced an additional GBP 500m share buyback and a 5% increase in interim dividend. Total capital returned since strategy launch ~GBP 6.4bn.
- Solid Balance Sheet and Guidance ReiterationFree cash flow of GBP 419m in H1; net debt-to-EBITDA at 2.5x. Management reiterated full-year Core Reckitt like-for-like net revenue guidance of 4%–5% and adjusted operating profit margin guidance of 24.9%–25.6% for Core Reckitt & Mead Johnson with a stronger H2 expected.
- Category Strength in Germ Protection and Self-careGerm Protection grew 10.5% in H1 (driven by Dettol and Lysol); Self-care grew 2.4% in H1 with VMS strength in China and strong Gaviscon performance across regions.
DE:3RB1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | 0.46- | 0.44 | ― | ― |
| Jul 29, 2026 | 2026 (Q2) | 0.340.24 | 0.35 | -32.24% (-0.11) | |
| Mar 05, 2026 | 2025 (Q4) | 0.460.44 | 0.45 | -2.77% (-0.01) | |
| Jul 24, 2025 | 2025 (Q2) | 0.410.35 | 0.39 | -8.31% (-0.03) | |
| Mar 06, 2025 | 2024 (Q4) | 0.360.45 | 0.24 | 84.98% (+0.21) | |
| Jul 24, 2024 | 2024 (Q2) | 0.370.39 | 0.42 | -7.08% (-0.03) | |
| Feb 28, 2024 | 2023 (Q4) | 0.340.24 | 0.36 | -33.09% (-0.12) | |
| Jul 26, 2023 | 2023 (Q2) | 0.400.42 | 0.42 | -1.06% (-0.00) | |
| Mar 01, 2023 | 2022 (Q4) | 0.380.36 | 0.37 | -1.45% (-0.01) | |
| Jul 27, 2022 | 2022 (Q2) | 0.330.42 | 0.37 | 14.32% (+0.05) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
